Kura Oncology

Kura Oncology

Yahoo Finance • 14 days ago

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list. TheFly reported on June 12 that Guggenheim a... Full story

Yahoo Finance • last month

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinic... Full story

Yahoo Finance • 2 months ago

QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of QuickLogic Corp(NASDAQ:QUIK) fell in pre-market trading after the company reported worse-than-expected first-quarter financ... Full story

Yahoo Finance • 2 months ago

After-Hours Earnings Report for May 12, 2026 : FNV, NXT, OKLO, KRMN, REZI, ATRO, CAPR, AIP, EVLV, KURA, RLMD, GAIN

The following companies are expected to report earnings after hours on 05/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Franco-Nevada Corporation (FNV)is reporting for the quarter ending March 31,... Full story

Yahoo Finance • 2 months ago

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median durati... Full story

Yahoo Finance • 2 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the B... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrin... Full story

Yahoo Finance • 3 months ago

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CES... Full story

Yahoo Finance • 3 months ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 4 months ago

Kura Oncology GAAP EPS of -$0.92 misses by $0.18, revenue of $17.34M misses by $18.11M

* Kura Oncology press release [https://seekingalpha.com/pr/20425187-kura-oncology-reports-fourth-quarter-and-full-year-2025-financial-results] (KURA [https://seekingalpha.com/symbol/KURA]): Q4 GAAP EPS of -$0.92 misses by $0.18. * Reve... Full story

Yahoo Finance • 5 months ago

Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the twenty stocks on our list of best biotech stocks is Kura Oncology, Inc. TheFly reported on January 13 that Leerink Partners lowered the price targe... Full story

Yahoo Finance • 7 months ago

Kura Oncology rises following Jim Cramer comments

[Myeloid leukemia] syahrir maulana * A mention on the Dec. 19 episode of CNBC's "Mad Money" hosted by Jim Cramer of Kura Oncology (KURA [https://seekingalpha.com/symbol/KURA]) is sending shares of the biotech higher by 12% in Monday tra... Full story

Yahoo Finance • 7 months ago

Jim Cramer Discusses Kura Oncology as a Speculative Bet

Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the company’s $135 million milestone payment owing to its U.S. commercial sale of KOMZIFTI, Cramer commented: “That’s a lot.... Full story

Yahoo Finance • 7 months ago

Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML

[Acute myeloid leukemia] Hailshadow * Kura Oncology (KURA [https://seekingalpha.com/symbol/KURA]) and Kyowa Kirin (KYKOF [https://seekingalpha.com/symbol/KYKOF])(KYKOY [https://seekingalpha.com/symbol/KYKOY]) said that a combination of... Full story

Yahoo Finance • 7 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly... Full story

Yahoo Finance • 7 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a... Full story

Yahoo Finance • 7 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. co... Full story

Yahoo Finance • 8 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

SAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced KOMZIFTI™ (ziftomenib), the first and only once-daily oral menin inhib... Full story

Yahoo Finance • 8 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full app... Full story